Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease
- PMID: 16959224
- DOI: 10.1016/j.brainres.2006.08.035
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease
Abstract
Huntington's disease has an increase in the activated calpain, which is enhanced by the NMDA receptor activation. We investigated the neuroprotective effect of memantine in 3-nitropropionic acid (3NP)-induced striatal degeneration model. Either memantine (20 mg/kg/day) or PBS was intraperitoneally administered for five days with 3NP continuous infusion. In the memantine-treated group, the striatal lesion volume, the number of TUNEL+ cells, and Fluoro-Jade C+ degenerating neurons were all decreased. Memantine increased Bcl-xl and decreased Bax level. Memantine also exerted an inhibitory effect on the micro-calpain level and decreased the huntingtin proteolytic fragments. Those rats treated with memantine showed less degree of weight loss at 5 days. Subsequently, memantine was found to have neuroprotective effects and save striatal cells with decreasing calpain levels in the 3NP model of Huntington's disease.
Similar articles
-
Minocycline in phenotypic models of Huntington's disease.Neurobiol Dis. 2005 Feb;18(1):206-17. doi: 10.1016/j.nbd.2004.09.017. Neurobiol Dis. 2005. PMID: 15649711
-
Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.J Neurosci. 2003 Jun 15;23(12):5020-30. doi: 10.1523/JNEUROSCI.23-12-05020.2003. J Neurosci. 2003. PMID: 12832525 Free PMC article.
-
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.Neurobiol Dis. 2007 May;26(2):375-84. doi: 10.1016/j.nbd.2007.01.003. Epub 2007 Jan 25. Neurobiol Dis. 2007. PMID: 17336076
-
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.J Neurochem. 2005 Dec;95(6):1521-40. doi: 10.1111/j.1471-4159.2005.03515.x. Epub 2005 Nov 21. J Neurochem. 2005. PMID: 16300642 Review.
-
[Huntington's disease: cellular and molecular basis of pathology].Zh Vyssh Nerv Deiat Im I P Pavlova. 2014 Jul-Aug;64(4):359-75. Zh Vyssh Nerv Deiat Im I P Pavlova. 2014. PMID: 25723022 Review. Russian.
Cited by
-
An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development.Neurochem Res. 2023 Jun;48(6):1631-1647. doi: 10.1007/s11064-023-03868-1. Epub 2023 Feb 4. Neurochem Res. 2023. PMID: 36738367 Review.
-
Uncoupling oxidative/energy metabolism with low sub chronic doses of 3-nitropropionic acid or iodoacetate in vivo produces striatal cell damage.Int J Biol Sci. 2010 Apr 22;6(3):199-212. doi: 10.7150/ijbs.6.199. Int J Biol Sci. 2010. PMID: 20440403 Free PMC article.
-
Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.Biomedicines. 2022 Aug 5;10(8):1895. doi: 10.3390/biomedicines10081895. Biomedicines. 2022. PMID: 36009443 Free PMC article. Review.
-
IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin.PLoS One. 2009 Jun 2;4(6):e5768. doi: 10.1371/journal.pone.0005768. PLoS One. 2009. PMID: 19488402 Free PMC article.
-
Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.Neural Regen Res. 2016 Nov;11(11):1712-1726. doi: 10.4103/1673-5374.194708. Neural Regen Res. 2016. PMID: 28123400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
